- Home Page /
- Books /
- Medical Books /
- Pharmacology /
- Sulfasalazine/sorafenib: A novel antitumor combination ...
Item #:
10209148
Sulfasalazine/sorafenib: A novel antitumor combination therapy for HCC: Future prospectives
Item #:
10209148
€ 49
Price Details
Excluding Shipping & Custom charges ( Shipping and custom charges will be calculated on checkout )
*All items will import from US
0 ratings
Write a review
In stock
Imported from USA store
QTY:
Order now and get it around Saturday, July 18
Secured transaction
Ubuy works hard to protect your security and privacy. Our advanced payment security system ensures confidentiality by encrypting your information during transmission using AES (Advanced Encryption Standards) and SSL (Secure Socket Layer) protocols. Your payment details are 100% secure as we do not share your payment details with third party sellers.
Our Top Logistics Partners
Sulfasalazine/sorafenib combination therapy: A new hope for HCC patients. Now you can beat your cancer.
Buy Now Pay Later
Fast
Shipping
Free
Return*
Secure Packaging
100% Original Products
PCI DSS Compliance
ISO 27001 Certified
Note: Step Down Voltage Transformer required for using electronics products of US store (110-120). Recommended power converters Buy Now.
What Stands Out
Novel Combination
This therapy pairs sulfasalazine with sorafenib, creating a unique combination that enhances antitumor efficacy specifically targeting hepatocellular carcinoma (HCC), a common and aggressive liver cancer.
Future Prospects
The exploration of this innovative therapy opens new avenues for treatment in HCC management, potentially leading to improved outcomes and better patient survival rates compared to existing therapies.
Targeted Treatment
This combination approach specifically addresses the challenges of HCC, providing a tailored treatment option that may reduce side effects and improve the overall treatment experience for patients.
Product Details
| Item Weight | 1 lbs (450 grams) |
Who Should Buy?
-
Oncology Researchers
Ideal for researchers studying antitumor therapies and their potential synergistic effects in hepatocellular carcinoma.
-
Clinicians
Useful for healthcare professionals treating patients with advanced hepatocellular carcinoma looking for novel combination therapies.
-
Pharmacologists
Beneficial for pharmacologists focusing on drug interactions and the development of new treatment protocols for liver cancer.
-
General Public
Not suitable for non-medical individuals without expertise in oncology or pharmacology due to its complex content.
-
Adverse Reaction Concerns
Patients with history of severe adverse reactions to sulfasalazine or sorafenib should avoid this treatment combination.
-
Non-Oncology Fields
Not recommended for professionals outside oncology who are not focused or interested in cancer therapeutics.
Product Description
Sulfasalazine/sorafenib: A novel antitumor combination therapy for HCC: Future prospectives
Have any Query? Chat with us
Customer Questions & Answers
-
Question:
What is Sulfasalazinesorafenib?
Answer: Sulfasalazinesorafenib is an innovative combination therapy designed specifically for the treatment of hepatocellular carcinoma (HCC), which is the most common type of liver cancer. This therapy merges the anti-inflammatory effects of sulfasalazine with the targeted action of sorafenib, aiming to enhance overall treatment effectiveness. By addressing both the tumor itself and the inflammatory environment surrounding it, this combination may improve patient outcomes. Furthermore, healthcare providers might consider this combination in cases where standard therapies may not yield satisfactory results. -
Question:
How does Sulfasalazinesorafenib work?
Answer: The combination works through a dual-action mechanism. Sulfasalazine is known for its anti-inflammatory properties, which can potentially decrease tumor-promoting inflammation. In contrast, sorafenib is a well-established targeted therapy that inhibits kinase activity involved in cancer cell proliferation and angiogenesis. Together, these components may synergistically enhance the body’s ability to fight cancer by not only targeting the tumor directly but also mitigating the inflammatory processes that can foster tumor growth. -
Question:
Who can benefit from using Sulfasalazinesorafenib?
Answer: Patients diagnosed with hepatocellular carcinoma, particularly those who have not responded well to conventional therapies, may find this combination therapy beneficial. It may also be applicable for individuals dealing with advanced-stage liver cancer or those who experience inflammation as a complicating factor in their condition. Medical professionals would need to evaluate a patient's specific situation to determine if this approach aligns with their healthcare goals. -
Question:
What are the potential side effects of Sulfasalazinesorafenib?
Answer: As with any medication, potential side effects may include fatigue, gastrointestinal disturbances, and skin reactions. Sulfasalazine might also lead to changes in blood counts or allergic reactions in some patients. It's crucial for users to discuss these potential risks with their healthcare provider, who can provide guidance on monitoring and managing side effects. Understanding these effects can help patients make informed decisions about their treatment options. -
Question:
Is Sulfasalazinesorafenib FDA approved?
Answer: As of now, Sulfasalazinesorafenib as a specific combination is not FDA-approved. However, both components, sulfasalazine and sorafenib, are recognized individually for their respective therapeutic effects. Ongoing research and clinical trials may explore the potential for formal approval of this combination therapy as evidence of its efficacy and safety is gathered. Always consult healthcare professionals for updates regarding approvals and practice standards. -
Question:
What research supports the efficacy of Sulfasalazinesorafenib?
Answer: Research into the efficacy of Sulfasalazinesorafenib is emerging, with studies indicating that combination therapies may enhance treatment effectiveness for HCC over standard monotherapy. Clinical trials are being conducted to further investigate the benefits and mechanisms through which this combination operates. Ongoing publications and findings from these investigative trials will be crucial in establishing a stronger evidence base, potentially influencing future treatment protocols and guidelines. -
Question:
Can Sulfasalazinesorafenib be used alongside other treatments?
Answer: Patients may often use Sulfasalazinesorafenib in conjunction with other treatment modalities, such as chemotherapy or radiation, depending on their specific cancer treatment plan. It is essential for physicians to carefully assess the overall treatment strategy and monitor for any interactions. Collaborative discussions between patients and their healthcare teams can optimize treatment effectiveness and minimize potential side effects, leading to better outcomes in HCC management. -
Question:
What is the future prospect for Sulfasalazinesorafenib?
Answer: The future prospects for Sulfasalazinesorafenib appear promising, particularly as ongoing research continues to elucidate its effectiveness and safety profile. With advancements in cancer treatment strategies and targeted therapies, this combination may play a pivotal role in developing personalized medicine approaches for HCC. Ultimately, further studies could result in greater acceptance and utilization of this therapy within clinical practices, offering renewed hope for patients battling liver cancer. -
Question:
Where can I buy Sulfasalazinesorafenib in Ireland?
Answer: You can purchase Sulfasalazinesorafenib: A novel antitumor combination therapy for HCC: Future prospectives at Ubuy in Ireland. Ubuy provides a convenient online platform to explore this product, allowing you to access detailed descriptions and benefits associated with it. Their user-friendly interface makes it simple for you to find the product and gain access to additional information as needed. -
Question:
Is Sulfasalazinesorafenib suitable for all patients with liver cancer?
Answer: No, Sulfasalazinesorafenib is not suitable for all patients suffering from liver cancer. Each patient's case is unique, with varying factors such as the stage of cancer, overall health, and response to prior treatments influencing suitability. It is essential for patients to consult with their oncologist to evaluate their individual circumstances and determine the most appropriate treatment options tailored to their needs.
Pharmacology Editorial Review
No editorial reviews found
Customer Reviews & Ratings
1 customers ratings
-
5 Star
100%
-
4 Star
0%
-
3 Star
0%
-
2 Star
0%
-
1 Star
0%
Review this product
Share your thoughts with other customers
Platform Trust & Buyer Confidence
MT
Mohd
Verified buyer
“The product received very good packaging & safe…Thank You”
16 June 2026 · via Trustpilot
SJ
Shawati
Verified buyer
“Accurate delivery timing given”
16 June 2026 · via Trustpilot
YB
Youcef
Verified buyer
“Not madly expensive like I thought, and much quicker than promised.”
15 June 2026 · via Trustpilot
LM
Leila
Verified buyer
“Never dealt with Ubuy before, but everything worked out great. Seamless cross border purchasing and shipping. Thanks!”
6/7/2026 · via Trustpilot
KA
Kwame
Verified buyer
“The process was smooth, with clear communication and timelines. This was my 1st purchase and I am really impressed. I will definitely be coming back.”
12 June 2026 · via Trustpilot
Secure Checkout
Global Delivery
Easy Returns
Genuine Products
Product Price History
Important information
- Limitations : For products shipped internationally, please note that any manufacturer warranty may not be valid; manufacturer service options may not be available; product manuals, instructions, and safety warnings may not be in destination country languages; the products (and accompanying materials) may not be designed in accordance with destination country standards, specifications, and labeling requirements; and the products may not conform to destination country voltage and other electrical standards (requiring use of an adapter or converter if appropriate). The recipient is responsible for assuring that the product can be lawfully imported to the destination country. When ordering from Ubuy or its affiliates, the recipient is the importer of record and must comply with all laws and regulations of the destination country.
- Not all the products listed on Ubuy are for sale, as Ubuy is a global search engine. Products are subject to export/trade regulations.
€ 49
Order now and get it around Saturday, July 18
This item is not restrict in my country.(Please click on above link if this item is not restrict in your country, So our team will review and allow.)
QTY:
Secured transaction
PCI DSS compliant and ISO 27001:2022 certified, with encrypted payments and full buyer protection on every order.
Our Top Logistics Partners
Fastest cross-border delivery
Features & Benefits
- Novel antitumor combination therapy for HCC
- Provides a new metric of success for HCC treatment
- No gold standard treatment for HCC before
- A new hope for HCC patients
- Offers a potential solution for beating cancer
- Addresses the complexity of hepatocarcinogenesis
Ubuy Assurance
Experience worry-free shopping with 100% original products, PCI DSS-compliant payment security, ISO 27001-certified data protection, the fastest cross-border delivery, free returns *, and secure packaging on every order.